SOPHiA GENETICS (SOPH) Competitors

SOPHiA GENETICS (NASDAQ:SOPH) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Do analysts recommend SOPH or URGN?

SOPHiA GENETICS currently has a consensus target price of $8.00, suggesting a potential upside of 102.02%. Urogen Pharma has a consensus target price of $32.00, suggesting a potential upside of 78.97%. Given SOPHiA GENETICS's higher probable upside, research analysts plainly believe SOPHiA GENETICS is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Urogen Pharma	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more volatility & risk, SOPH or URGN?

SOPHiA GENETICS has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.

Is SOPH or URGN more profitable?

SOPHiA GENETICS has a net margin of -40.99% compared to Urogen Pharma's net margin of -164.44%. SOPHiA GENETICS's return on equity of -30.69% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-40.99%	-30.69%	-17.39%
Urogen Pharma	-164.44%	-97,487.15%	-59.38%

Does the media prefer SOPH or URGN?

In the previous week, SOPHiA GENETICS had 5 more articles in the media than Urogen Pharma. MarketBeat recorded 6 mentions for SOPHiA GENETICS and 1 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.78 beat SOPHiA GENETICS's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Urogen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has better valuation & earnings, SOPH or URGN?

SOPHiA GENETICS has higher earnings, but lower revenue than Urogen Pharma. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$65.17M	4.11	-$62.49M	-$0.44	-9.00
Urogen Pharma	$90.40M	9.15	-$126.87M	-$3.32	-5.39

Do insiders & institutionals hold more shares of SOPH or URGN?

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

SOPHiA GENETICS and Urogen Pharma tied by winning 8 of the 16 factors compared between the two stocks.